The Effect of Triple Therapy With Exenatide, Dapagliflozin, and Metformin on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

January 5, 2018. DURATION-8 was a 28-week, phase 3, randomized controlled trial evaluating the efficacy and safety of exenatide once weekly (QW) + dapagliflozin vs either drug alone, all added to metformin monotherapy in 695 patients with type 2 diabetes. This post-hoc analysis grouped patients according to their baseline body weight, systolic blood pressure (SBP), and triglyceride levels and then assessed the impact of exenatide QW + dapagliflozin, exenatide QW, or dapagliflozin on these risk factors. Most subgroups saw reductions in each variable, and there were no significant subgroup-by-treatment interactions. However, combination therapy with exenatide QW + dapagliflozin reduced body weight, SBP, and triglycerides from baseline more than exenatide QW or dapagliflozin alone. The greatest treatment effects were seen in patient subgroups with higher baseline values for body weight and SBP. You can read the study abstract here.